Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer
The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer.
Gastric Cancer
DRUG: SHR6390
Maximum Tolerated Dose (MTD), 42 days
Maximum Plasma Concentration, 42 days|Area Under the Curve, 42 days
The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer.